The Role of Cytokines in the Metastasis of Solid Tumors to the Spine: Systematic Review

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Feb 25

PMID 36835198

Authors

Wojciech Labedz

Anna Przybyla

Agnieszka Zimna

Mikolaj Dabrowski

Lukasz Kubaszewski

Affiliations

Soon will be listed here.

Abstract

Although many studies have investigated the role of cytokines in bone metastases, our knowledge of their function in spine metastasis is limited. Therefore, we performed a systematic review to map the available evidence on the involvement of cytokines in spine metastasis in solid tumors. A PubMed search identified 211 articles demonstrating a functional link between cytokines/cytokine receptors and bone metastases, including six articles confirming the role of cytokines/cytokine receptors in spine metastases. A total of 68 cytokines/cytokine receptors were identified to mediate bone metastases; 9 (mostly chemokines) played a role in spine metastases: CXC motif chemokine ligand (CXCL) 5, CXCL12, CXC motif chemokine receptor (CXCR) 4, CXCR6, interleukin (IL) 10 in prostate cancer, CX3C motif chemokine ligand (CX3CL) 1 and CX3C motif chemokine receptor (CX3CR) 1 in liver cancer, CC motif chemokine ligand (CCL) 2 in breast cancer, and transforming growth factor (TGF) β in skin cancer. Except for CXCR6, all cytokines/cytokine receptors were shown to operate in the spine, with CX3CL1, CX3CR1, IL10, CCL2, CXCL12, and CXCR4 mediating bone marrow colonization, CXCL5 and TGFβ promoting tumor cell proliferation, and TGFβ additionally driving bone remodeling. The number of cytokines/cytokine receptors confirmed to mediate spinal metastasis is low compared with the vast spectrum of cytokines/cytokine receptors participating in other parts of the skeleton. Therefore, further research is needed, including validation of the role of cytokines mediating metastases to other bones, to precisely address the unmet clinical need associated with spine metastases.

Citing Articles

CCL5/CCR5/CYP1A1 pathway prompts liver cancer cells to survive in the combination of targeted and immunological therapies.

Wang Y, Gao B, Jiao T, Zhang W, Shi H, Jiang H Cancer Sci. 2024; 115(11):3552-3569.

PMID: 39183447 PMC: 11531955. DOI: 10.1111/cas.16320.

Mts1 (S100A4) and Its Peptide Demonstrate Cytotoxic Activity in Complex with Tag7 (PGLYRP1) Peptide.

Yurkina D, Romanova E, Shcherbakov K, Ziganshin R, Yashin D, Sashchenko L Int J Mol Sci. 2024; 25(12).

PMID: 38928339 PMC: 11203719. DOI: 10.3390/ijms25126633.

Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis.

Arakil N, Akhund S, Elaasser B, Mohammad K Biomedicines. 2024; 12(5).

PMID: 38791037 PMC: 11117796. DOI: 10.3390/biomedicines12051075.

Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges.

Yu X, Zhu L Int J Nanomedicine. 2024; 19:1867-1886.

PMID: 38414525 PMC: 10898486. DOI: 10.2147/IJN.S442768.

References

Conley-LaComb M, Semaan L, Singareddy R, Li Y, Heath E, Kim S . Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis. Mol Cancer. 2016; 15(1):68. PMC: 5093938. DOI: 10.1186/s12943-016-0552-0. View

Roca H, Jones J, Purica M, Weidner S, Koh A, Kuo R . Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest. 2017; 128(1):248-266. PMC: 5749545. DOI: 10.1172/JCI92466. View

Wan X, Li Z, Yingling J, Yang J, Starbuck M, Ravoori M . Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2011; 50(3):695-703. PMC: 3278589. DOI: 10.1016/j.bone.2011.11.022. View

Buenrostro D, Kwakwa K, Putnam N, Merkel A, Johnson J, Cassat J . Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner. Bone. 2018; 113:77-88. PMC: 6118216. DOI: 10.1016/j.bone.2018.05.008. View

Xing Y, Liu M, Du Y, Qu F, Li Y, Zhang Q . Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach. Cancer Biol Ther. 2008; 7(11):1839-48. DOI: 10.4161/cbt.7.11.6862. View

Bendre M, Montague D, Peery T, Akel N, Gaddy D, Suva L . Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003; 33(1):28-37. DOI: 10.1016/s8756-3282(03)00086-3. View

Ma N, Pang H, Shen W, Zhang F, Cui Z, Wang J . Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo. Int J Mol Med. 2014; 35(2):425-32. DOI: 10.3892/ijmm.2014.2033. View

Deckers M, van Dinther M, Buijs J, Que I, Lowik C, van der Pluijm G . The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res. 2006; 66(4):2202-9. DOI: 10.1158/0008-5472.CAN-05-3560. View

Biswas S, Nyman J, Alvarez J, Chakrabarti A, Ayres A, Sterling J . Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone. PLoS One. 2011; 6(11):e27090. PMC: 3214031. DOI: 10.1371/journal.pone.0027090. View

10.

Shupp A, Kolb A, Mukhopadhyay D, Bussard K . Cancer Metastases to Bone: Concepts, Mechanisms, and Interactions with Bone Osteoblasts. Cancers (Basel). 2018; 10(6). PMC: 6025347. DOI: 10.3390/cancers10060182. View

11.

Zhang L, Yeger H, Das B, Irwin M, Baruchel S . Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma. Neoplasia. 2007; 9(1):36-46. PMC: 1803034. DOI: 10.1593/neo.06670. View

12.

Trivedi T, Pagnotti G, Guise T, Mohammad K . The Role of TGF-β in Bone Metastases. Biomolecules. 2021; 11(11). PMC: 8615596. DOI: 10.3390/biom11111643. View

13.

Petersen M, Pardali E, Van Der Horst G, Cheung H, van den Hoogen C, van der Pluijm G . Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene. 2009; 29(9):1351-61. DOI: 10.1038/onc.2009.426. View

14.

Hu Z, Gupta J, Zhang Z, Gerseny H, Berg A, Chen Y . Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther. 2012; 23(8):871-82. PMC: 3413899. DOI: 10.1089/hum.2012.040. View

15.

Wang N, Docherty F, Brown H, Reeves K, Fowles A, Ottewell P . Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models. J Bone Miner Res. 2014; 29(12):2688-96. DOI: 10.1002/jbmr.2300. View

16.

Lim S, Yuzhalin A, Gordon-Weeks A, Muschel R . Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget. 2016; 7(19):28697-710. PMC: 5053756. DOI: 10.18632/oncotarget.7376. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Ban J, Fock V, Aryee D, Kovar H . Mechanisms, Diagnosis and Treatment of Bone Metastases. Cells. 2021; 10(11). PMC: 8616226. DOI: 10.3390/cells10112944. View

19.

Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L . Bone Metastases: An Overview. Oncol Rev. 2017; 11(1):321. PMC: 5444408. DOI: 10.4081/oncol.2017.321. View

20.

Gnant M, Pfeiler G, Dubsky P, Hubalek M, Greil R, Jakesz R . Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(9992):433-43. DOI: 10.1016/S0140-6736(15)60995-3. View